Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study
Garadacimab has a favorable safety profile suitable for long-term use and provides durable protection against HAE attacks.
Authors
- Keiko Yamagami (ORCID: https://orcid.org/0000-0001-9099-7673)
- Avner Reshef (ORCID: https://orcid.org/0000-0002-3324-7072)
- Constance H. Katelaris (ORCID: https://orcid.org/0000-0002-4412-1336)
- Philip Hei Li (ORCID: https://orcid.org/0000-0002-9155-9162)
- Mar Guilarte (ORCID: https://orcid.org/0000-0001-7242-9584)
- Connie Hsu (ORCID: https://orcid.org/0000-0001-8951-8903)
- Paul K. Keith (ORCID: https://orcid.org/0000-0002-5644-1855)
- Lolis Wieman
- Markus Magerl (ORCID: https://orcid.org/0000-0001-9218-5468)
- Maressa Pollen
- Jonathan A. Bernstein (ORCID: https://orcid.org/0000-0002-3476-1196)
- John‐Philip Lawo (ORCID: https://orcid.org/0000-0002-4321-176X)
- H. Shekar Shetty
- Tim J. Craig
Institutions
- Camden and Campbelltown Hospitals (AU)
- McMaster University Medical Centre (CA)
- Barzilai Medical Center (IL)
- Humboldt-Universität zu Berlin (DE)
- Osaka City General Hospital (JP)
- Clinical Research Solutions (US)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Vinmec Times City International Hospital (VN)
- Bernstein Clinical Research Center (US)
- CSL (United States) (US)
- Vall d'Hebron Hospital Universitari (ES)
- University of Cincinnati (US)
- Western Sydney University (AU)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Penn State Milton S. Hershey Medical Center (US)
- University of Hong Kong (HK)
Publication Details
- Journal
- Allergy
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1111/all.16351
- Citations
- 22
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 9.63
Funders
- CSL Behring